Averna Therapeutics

Averna Therapeutics is at the forefront of biotechnology, dedicated to developing innovative ribonucleic acid (RNA) and lipid nanoparticle (LNP)-based genomic medicines. Averna Therapeutics focuses on creating durable and safe treatments for a wide array of diseases, including genetic disorders, cancer, and autoimmune conditions.

With proprietary technology rooted in a natural system, Averna Therapeutics inserts therapeutic genetic instructions into 'safe harbor' sites within the genome. These genomic regions ensure stable gene integration without disrupting normal cell function, offering a groundbreaking approach to treatment. Averna Therapeutics’ medicines, encoded in RNA, utilize validated, non-viral delivery platforms that are safe, efficient, scalable, and cost-effective, allowing for redosing with curative intent.

Averna Therapeutics is committed to advancing RNA/LNP-based genomic medicines that deliver meaningful solutions for patients. We invite the manager of Averna Therapeutics to create a customized and exclusive company showcase and product listing on our platform to further highlight their innovative work.